VIVUS Inc (VVUS.OQ)
1 Jul 2016
* Vivus Inc says to extend return date of Stendra commercial rights
BRIEF-Vivus receives notice from Hetero USA that it has filed with U.S. FDA ANDA for generic versions of all strengths of Stendra tablets
* Received notice from Hetero USA that it has filed with U.S. FDA ANDA for generic versions of all strengths of Stendra tablets
|Takeda Pharmaceutical Co Ltd (4502.T)||¥4,438||+14.00|
|Eisai Co., Ltd (4523.T)||¥5,795||+107.00|
|Novo Nordisk A/S (NOVOb.CO)||kr.363.50||+5.40|
|Pfizer Inc. (PFE.N)||$35.57||+0.36|
|Merck & Co., Inc. (MRK.N)||$57.94||+0.33|
|Roche Holding Ltd. (ROG.S)||CHF256.70||+0.60|
|Roche Holding Ltd. (RO.S)||CHF260.00||+1.75|
|GlaxoSmithKline plc (GSK.L)||1,600.00p||-4.50|
|Eli Lilly and Co (LLY.N)||$78.95||+0.20|
|Arena Pharmaceuticals, Inc. (ARNA.OQ)||$1.66||-0.05|
Earnings vs. Estimates
Analyst Research Reports
Provider : Thomson Reuters Stock Report
Trading Report for (VVUS). A detailed report, including free correlated market analysis, and updates.
Provider : Stock Traders Daily
Provider : New Constructs, LLC
Provider : ValuEngine, Inc.
Provider : S&P Capital IQ Quantitative Report
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.